



ANNUAL REPORT 2016



The Face
of Research

An abstract graphic consisting of several overlapping, wavy, light blue lines that curve from the top right towards the bottom left, creating a sense of movement and depth.

Inside

- 1 **Letter from Leadership**
- 2 **Advocacy Overview**
- 4 **Campaign for Cures**
- 5 **Post-Election Briefing**
- 6 **2016 Advocacy Awards**
- 7 **2016 National Health Research Forum**
- 8 **Dedication of the Paul G. Rogers Conference Room**
- 9 **BIO Session: A World Without Disease**
Medical and Health Research and the Economy
- 10 **Research!America President and CEO Honored
for Leadership and Advocacy**
- 11 **Motivating Research Advocates**
- 12 **U.S. Investments in Medical and Health R&D Report**
Public Health Thank You Day
- 13 **Research Across the Continuum**
- 14 **Media Highlights**

Inserts

Research!America Membership
Investment in Research and U.S. Biomedical Innovation
Research!America Financial Statements
Scientific Advisory Committee

Research!America is the nation's largest 501(c)(3) alliance working to make research to improve health a higher national priority. Research!America's member organizations together represent the voices of more than 125 million Americans. Our public opinion surveys, advocacy programs, and publications reach the public and decision-makers to help advance medical, health and scientific research.

Letter from Leadership


2016 was a pivotal year for research and innovation as we saw the enactment of the bipartisan 21st Century Cures Act, rightly hailed as a landmark achievement. The measure is a testament to the perseverance of research advocates who believe in better—a better life, a better economy and a better research ecosystem—with all elements fine-tuned to accelerate the discovery, development and delivery of new treatments, preventions, cures and medical devices for patients.

Passage of the Act was a clear statement that advocacy works! Partnering with member organizations, Research!America increased our presence on Capitol Hill, calling attention to the urgency of realizing the promise of research in both the public and private sector. Our briefings, workshops and other high-impact programs attracted leaders in academia, government, industry, patient groups and scientific societies. Our voice in support of 21st Century Cures was heard early and often in the media.

The 2016 election engaged our attention as candidates for national office debated selected issues of the day. The Campaign for Cures national voter education initiative empowered scientists and voters to connect with candidates, urging them to assign a higher priority to research for health, and for research and innovation broadly. We have a robust database of relevant quotes from nearly 350 members of the new Congress at our fingertips to inform advocacy going forward.

Many members of Congress, across the political spectrum, value the tangible, intangible and far-reaching benefits of medical and health research, not only from a personal standpoint but from an economic and global competitiveness standpoint. They recognize that research is critical to healthy communities and our ability to prevent, contain and eradicate global health threats that impact our national security. State-based programming in Louisiana, Colorado, Ohio and Georgia enabled us to strengthen relationships with leaders in research as well as elected officials in those states, and work with both to raise the level of attention and support for achieving faster medical progress.

Moving forward, we will continue to hold elected officials accountable and to insist that decisions are driven by evidence as new policies, legislative and executive actions affect scientific pursuits, the careers of young scientists, and public and private sector research and innovation. Scientists must also do their part to put a face on research. We will continue to work with scientists to help them increase their comfort level in engagement with non-scientists and build relationships that will significantly broaden appreciation for science among the public and policymakers. There's no question that it's important for all of us to work together to ensure that science and innovation is a strategic imperative for our nation. There's no time to waste.



**The Honorable
John Edward Porter**
Chair

A stylized, handwritten signature of John Edward Porter in black ink.



Mary Woolley
President and CEO

A handwritten signature of Mary Woolley in black ink.

Advocacy Overview

The benefits of medical and health research and a rock-solid public health system are profound.



Elevating Medical and Health Research in our Nation

In 2016, Research!America and our more than 380 alliance member organizations worked intensely to strengthen policymaker and public support for research. We participated in 160 congressional meetings, held 25 meetings with executive branch officials, and facilitated more than 2,300 messages to Congress.

We published 35 new fact sheets, infographics and other advocacy and public education materials, including a new state-by-state fact sheet series. We sent and signed onto 53 letters and statements directed to members of Congress and the Obama Administration in 2016. Research!America sent letters to Congress advocating for robust fiscal year 2017 (FY17) funding for the National Institutes of Health (NIH), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ) and National Science Foundation (NSF); joined forces with the Aerospace Industries Association to describe the harmful consequences of long-term continuing resolutions (CR); sponsored a sign-on letter on the same topic that garnered more than 250 signatures; and sent a letter to House and Senate leadership to request Congress provide emergency funding to combat the Zika virus.

Community Engagement


Research!America partnered with our members to support advocacy days, as well as a month of action in August focused on securing passage of the 21st Century Cures Act. We sponsored a sign-on letter in support of the Cures bill that garnered more than 180 signatures. The final Cures legislation passed the House and Senate overwhelmingly, providing vital funding to NIH and FDA, and initiating policy changes to help responsibly speed the discovery, development and delivery of new medical advances.

Additionally, Research!America hosted several webinars including one with Stefano Bertuzzi, Ph.D., MPH, executive director and CEO of the American Society for Microbiology, for a highly engaging discussion about the microbiome, communities of microorganisms vital to our bodies, our ecosystems and our world.

Looking Ahead

Throughout 2016, we witnessed strong support for research and innovation, as well as increased awareness of the crucial role our public health agencies play. However, the year ended without resolution of FY17 funding; absent congressional action and a return of austerity level budget caps; the medical device tax suspension will expire at the end of 2017; the Prevention and Public Health Fund is at grave risk; and other challenges lie ahead.

Research!America will continue to expand and diversify our advocacy efforts as we fight for the funding and policies needed to fuel faster public and private-sector medical discovery; a public health system that is fully equipped to meet its lifesaving mission; health services, health economics and social sciences research that is pivotal to the future of health and health care; and a stronger national commitment to our nation's unparalleled science and engineering enterprise.



Do you agree or disagree
that public policies should be
**based on the
best available science?**

Source: A Research!America survey of U.S. adults conducted
in partnership with Zogby Analytics in January 2017.

2016

KEY ACCOMPLISHMENTS

More Visibility on Capitol Hill

Increased Research!America's—and our members'—presence in advocating for public and private sector research.

21st Century Cures Act

Worked closely with research stakeholders to increase bipartisan congressional support for Cures legislation.

National Voter Education Initiative

Significantly expanded our election-year commitment to assuring that more candidates for office assign a high-priority to research and innovation.

State-Based Programs

Conducted state programs in Louisiana, Colorado, Ohio and Georgia, and expanded our base of advocates.

Advocacy and Science Communications Workshops

Trained and educated hundreds of scientists to be more effective advocates.



Campaign for Cures

Research!America's national voter education initiative, Campaign for Cures: Vote for Medical Progress, launched in 2015, focused on elevating the importance of research and innovation during the election season. Through strategic grassroots activities, communication initiatives and partnerships, the initiative helped raise awareness about the views of congressional and presidential candidates on medical progress and empowered research advocates to engage with candidates.



The Campaign for Cures website featured an interactive map of the U.S. with more than 500 quotes on public and private sector research from candidates across the political spectrum running for national office.

The Campaign for Cures blog, managed by former *USA Today* senior editor and health reporter Janice Lloyd, featured commentary, election news, public opinion survey data, and an analysis of presidential and congressional races on topics relevant to medical progress. During October 2016, a Campaign for Cures online ad ran in key states urging voters to ask candidates whether medical progress is among their priorities.


On the Ground Events

Research!America participated in and hosted several on-the-ground events, including a town hall at American Public Health Association's 2016 Annual Meeting, panel discussions at Georgia's BIO Summit and the Louisiana Research Summit. President and CEO Mary Woolley joined AAAS CEO Rush Holt, Ph.D., and Nobel Laureate Harold Varmus, M.D., and other panelists for a program titled "A More Scientific Union," hosted by ScienceDebate.org, Research!America and other leading scientific organizations that aired on the Young Turks YouTube Network.

ScienceDebate.org and Research!America commissioned a public opinion survey which showed that a majority of Americans (87%) say candidates should have a basic understanding of science informing public policy, among other key findings. The survey data and information about Campaign for Cures were featured in media outlets across the country and social media messages generated millions of impressions.

In your view, how important is it for President Trump to assign a high priority to putting health research and innovation to work to assure continued medical progress?

Source: A Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in June 2016.





(L to R) Lori Stokes; Hon. Lou Sullivan, M.D.; Rush Holt, Ph.D.; Hon. John Edward Porter; Hon. Mike Castle

PHOTOS THIS PAGE: STEPHEN BOBB PHOTOGRAPHY


Research in a New Administration

● Post-Election Briefing

Research!America convened an esteemed panel of policymakers for the 2016 Post-Election Briefing on November 15 to discuss expectations for science and medical progress with a new President and the next Congress. The briefing was hosted by the American Association for the Advancement of Science and supported in part by Zogby Analytics.

John Zogby, founder and senior partner of John Zogby Strategies and internationally respected pollster, said that while it's too soon to tell what a Trump Administration will mean for medical and health research, Americans agree that research is vital to our nation. Following his remarks, a panel comprised of Research!America Chair Hon.

John Porter; Vice Chair Gov. Mike Castle; American Association for the Advancement of Science CEO and board member Rush Holt, Ph.D.; and the Hon. Lou Sullivan, M.D., former U.S. Secretary of Health and Human Services discussed the outlook of research funding and policies that impact public and private sector research. Lori Stokes, co-anchor, WABC-TV Eyewitness News and daughter of the late Ohio Congressman Louis Stokes, moderated the panel.



John Zogby

The discussion touched on the uncertainty of the future of the Cancer Moonshot, challenges to recruit and retain top talent in federal science agencies and adequate funding for the agencies. With the new Administration, Holt said there are more questions than answers, including whether evidence-based science will guide decision-making.

The panelists emphasized that it's important for advocates to speak out now more than ever to ensure science is a national priority moving forward. Porter urged scientists to meet with their representatives "and tell them what you do and why it makes a difference." Often policymakers don't have that information, he said, and if they knew it, they'd act on it.

2016 Advocacy Awards

● Honorees

The contributions of Research!America's 2016 Advocacy Awards honorees have transformed medical research, advocacy for research, patient engagement and biotechnology. Their efforts have led to significant advances in cancer and Alzheimer's research, the development of innovative technologies, and created a groundswell of public support to find treatments and a cure for amyotrophic lateral sclerosis (ALS). The honorees were recognized for their achievements in research advocacy on March 16 at the Andrew W. Mellon Auditorium in Washington, D.C.

EDWIN C. WHITEHEAD AWARD FOR MEDICAL RESEARCH ADVOCACY

Senator Roy Blunt (R-MO) and Representative Tom Cole (R-OK) for their steadfast commitment to increasing federal investments in research to advance innovative studies focused on preventing and eradicating diseases that take a tremendous toll on families and our economy.

LEGACY AWARD

Harold Varmus, M.D., co-recipient of the Nobel Prize for studies of the genetic basis of cancer, and the Meyer Cancer Center of Weill Cornell Medical College Lewis Thomas University Professor of Medicine, for his lifelong career and leadership in research as the director of the National Cancer Institute (2010-2015), president of Memorial Sloan-Kettering Cancer Center (2000-2010) and director of the National Institutes of Health (1993-1999).

GEOFFREY BEENE BUILDERS OF SCIENCE AWARD

John H. Noseworthy, M.D., president and chief executive officer of Mayo Clinic, for his leadership in ensuring Mayo Clinic remains a trusted resource for patients amid a rapidly changing health care environment, extending Mayo's mission to new populations, providing care through more efficient delivery models, and increasing the personalization and immediacy of health care for all people.

GORDON AND LLURA GUND LEADERSHIP AWARD

George and Trish Vradenburg, co-founders of UsAgainstAlzheimer's (UsA2), an organization advancing solutions to the Alzheimer's challenge. UsA2 speaks for persons with or at risk for Alzheimer's in pressing for greater urgency from government, industry and the scientific community—accomplishing this through sustained and relentless leadership and fierce advocacy.



Harold Varmus, M.D.

ISADORE ROSENFELD AWARD FOR IMPACT ON PUBLIC OPINION

Lisa Paulsen and The Entertainment Industry Foundation for Stand Up To Cancer (SU2C), EIF's largest initiative, established in 2008 by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease.

RAYMOND AND BEVERLY SACKLER AWARD FOR SUSTAINED NATIONAL LEADERSHIP

Robert Langer, Sc.D., David H. Koch Institute Professor at MIT, for being a passionate advocate for basic research and its role in solving real world problems, even as his research has advanced the practice of medicine and changed the quality of people's lives. Dr. Langer is one of very few individuals ever elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.

PAUL G. ROGERS DISTINGUISHED ORGANIZATION ADVOCACY AWARD

The ALS Association, as the preeminent ALS organization, leads the way in research, care services, public education, and public policy—giving help and hope to those coping with the disease. The first ALS Ice Bucket Challenge in the summer of 2014 became the world's largest global social media phenomenon. It is now an annual event to raise awareness and funds to find treatments and a cure for amyotrophic lateral sclerosis (ALS).



(L to R) Hon. Kweisi Mfume, Research!America Board Member; Lorri Carey, The ALS Association; Barbara Newhouse, The ALS Association



(L to R) Taoist Monk Yunrou; Lisa Paulsen



Hon. Tom Cole; Hon. Michael Castle, Research!America Board Vice Chair; Hon. Roy Blunt



(L to R) Robert Langer, Sc.D.; Tenley Albright, M.D., Massachusetts Institute of Technology, Research!America Board Member



(L to R) Elias A. Zerhouni, M.D., Sanofi, Research!America Board Member; George & Trish Vradenburg; Hussein Manji, M.D., Janssen Research & Development, LLC



(L to R) Mara Hutton, Geoffrey Beene Foundation; Ronald Petersen, M.D., Ph.D.; Tom Hutton, Geoffrey Beene Foundation

PHOTOS THIS PAGE: THOMAS VAN VEEN



(L to R) Nsikan Akpan; France Córdova, Ph.D.; John Danaher, M.D., MBA; Donna Cryer, JD; Albert Lauritano, M.S., BD; Keith Yamamoto, Ph.D.; Anthony Fauci, M.D.

Experts Discuss Future of Research

● 2016 National Health Research Forum

The time is now to renew our nation's commitment to the biomedical research enterprise.

In order to meet health challenges, William N. Hait, M.D., Ph.D., global head, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, said robust investments in research to find cures and preempt disease before illness occurs are necessary.

Hait was the keynote speaker at Research!America's 2016 National Health Research Forum. The program, "Straight Talk: New Thinking on Tough Challenges," held Thursday, September 8 at the News-um in Washington, D.C., featured panel discussions with leaders representing academia, industry, patient groups, government and scientific societies. Janssen Pharmaceutical Companies of Johnson & Johnson was the lead sponsor of the event.

"Looking forward, 10, 20 years from now, we can't take our eye off the importance of the stability of the biomedical research enterprise."

Anthony Fauci M.D., director, National Institute of Allergy and Infectious Diseases

Taking Stock and Looking Ahead

The first panel provided insights into bold initiatives including the Cancer Moonshot and the BRAIN Initiative that have led to more collaboration between the public and private sector and patient engagement. Speakers discussed the need for a standing public health emergency fund to help respond to threats such as Zika.

Moderator: Nsikan Akpan, digital science producer, PBS NewsHour

Panelists: France A. Córdova, Ph.D., director, National Science Foundation; Donna R. Cryer, JD, president and CEO, Global Liver Institute; John W. Danaher, M.D., MBA, president, Elsevier Education, Elsevier; Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Albert A. Lauritano, M.S., CLP, director, strategic technology partnerships, BD; Keith R. Yamamoto, Ph.D., vice chancellor for science policy and strategy; vice dean for research, School of Medicine, University of California, San Francisco.

Going Bold

Panelists discussed the role of prevention research as it relates to emerging infectious diseases, pain management and opioid abuse, antimicrobial resistance and other conditions. Speakers also described how social determinants of health impact the prevalence of chronic disease in underserved communities.

Moderator: Natalie Azar, M.D., medical contributor, NBC News

Panelists: Hortensia Amaro, Ph.D., associate vice provost for community research initiatives and dean's professor of social work and preventive medicine, University of Southern California; Andrew B. Bindman, M.D., director, Agency for Healthcare Research and Quality; Anne Schuchat, M.D., principal deputy director, Centers for Disease Control and Prevention; William N. Hait, M.D., Ph.D., global head, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Joe V. Selby, M.D., MPH, executive director, Patient-Centered Outcomes Research Institute; Stephen D. Silberstein, M.D., FAHS, FACP, professor of neurology, director of the Jefferson Headache Center, Thomas Jefferson University.

Future Forward

The mission of the Food and Drug Administration was the focus of the third panel, including the agency's current priorities, the importance of a strong workforce and how the agency plans to evolve in approving new drugs and medical devices to meet patients' needs.

Moderator: Geneva Overholser, senior fellow and consultant of the Democracy Fund, and former national syndicated columnist and editor

Panelists: Robert M. Califf, M.D., commissioner, Food and Drug Administration; Emil Kakkis, M.D., Ph.D., president and founder, EveryLife Foundation for Rare Diseases; The Honorable Kweisi Mfume, former U.S. Representative, 1987-1996; Sudip S. Parikh, Ph.D., senior vice president and managing director, DIA Global; Jean-Christophe Tellier, M.D., CEO, chairman of the Executive Committee, UCB.



Dedication of the Paul G. Rogers Conference Room

Friends, family and former colleagues paid tribute to the late Honorable Paul G. Rogers during a dedication ceremony on December 8 for the conference room named in his honor at Research!America's new office in Arlington, Virginia.

Rogers was elected to Congress in 1955 and served until 1979. During his time as a Florida representative, he rose through the ranks to chair the House Subcommittee on Health and the Environment. His long list of legislative accomplishments included the Clean Air Act, the Community Health Centers Act and the National Cancer Act.

Research!America chair The Honorable John Edward Porter read remarks from Supreme Court Chief Justice John Roberts, who wrote that Rogers "was an extraordinarily effective advocate for public health initiatives, and he was admired and respected by all" and observed that the dedication was a "well-deserved tribute to a truly remarkable man."

The Honorable Dan Mica, who succeeded Rogers in Congress, said his friend and mentor was a consensus builder who worked across the political aisle to get things done.

Widely known as "Mr. Health", Rogers' advocacy work earned him many awards, including the Albert Lasker

Award for Public Service and the Research!America Edwin C. Whitehead Award for Medical Research Advocacy. He chaired Research!America from 1996 until 2005, and as Chair Emeritus until his death in 2008. His daughter Laing Rogers Sisto maintains his legacy as a member of Research!America's board.

"Without research, there is no hope," one of Rogers' most cited quotes, is now emblazoned along the glass wall of the conference room and serves as a reminder of the important work ahead in research advocacy.

The Paul G. Rogers conference room was made possible by a gift from the Rogers Family Foundation.

***"Without research,
there is no hope."***

The Honorable Paul G. Rogers

BIO Session: A World Without Disease

Immorbidity—a perspective on health in which the priority shifts from treating or curing diseases to preventing, intercepting and halting the progression of disease—was the topic of discussion at a session organized by Research!America at the BIO International Convention on June 8. Research!America board members Keith Yamamoto, M.D., executive vice dean of the School of Medicine at the University of California, San Francisco, and William N. Hait, M.D., global head, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, participated in a conversation titled “Lifespan or Healthspan: Is it Time for a Paradigm Shift?” which addressed the rationale for shifting investments from post-symptom to pre-symptom care.

Hait noted that most individuals begin developing chronic diseases before age 50. The goal, he said, is to create a world without disease by 2030, shifting the focus from treating disease to measuring risk of disease and then investigating its causes. The weakest link in the chain, he added, is behavioral science. We need “the brightest minds” to work in that field to prevent diseases individuals are susceptible to from becoming a reality. Precision medicine also plays a critical role in aggregating biological data to reveal patterns and disparate

information about an individual’s health, Yamamoto said. Articulating the concept of creating a world without disease in terms similar to putting a man on the moon will spark people’s imaginations and encourage research sectors to collaborate, he noted. During introductory remarks, Research!America president and CEO Mary Woolley said in order to further medical progress, the conversation can’t be about “cutting costs or cutting corners.” It’s about empowering innovation and putting every sector of the research ecosystem to work, she stressed.



(L to R) Keith Yamamoto, M.D.; William Hait, M.D.

Medical and Health Research and the Economy

The U.S. is well positioned to maintain its preeminence in biomedical research even as other countries ramp up their investments in research and development, according to Walter Koroshetz, M.D., director of the National Institute of Neurological Disorders and Stroke (NINDS). “The good news is that we have tremendous ability to bring young people into the science field and give them the tools and the knowledge to compete against anybody in the world but it is not something that happens on serendipity, it happens on planning, investment and foresight,” he said. Global competitiveness, public-private partnerships, federal funding and other issues impacting medical research, the economy and public health were the focus of the panel discussion “Medical Research: The Right Prescription for Economic Growth,” hosted by Northeast Ohio Medical University (NEOMED) in Rootstown, Ohio on June 6.

The event was livestreamed and attended by members of the Ohio congressional delegation, business leaders, university presidents from across the state, research leaders and scientists. The panel was moderated by Susan Dentzer, president and CEO, The Network for Excellence in Health Innovation and Research!America board member, and the panelists included Dr. Koroshetz; Sudip Parikh, Ph.D., senior vice president and managing director, DIA and Research!America board member; Michael Drake, M.D., president, Ohio State University; Joe Kanfer, chairman and CEO, GOJO Industries; Thomas Zenty, CEO, University Hospitals; Lucinda Maine, Ph.D., R.Ph., EVP and CEO, American Association of Colleges of Pharmacy and Research!America board member. Research!America president and CEO Mary Woolley released new public opinion survey data highlighting Ohioans’ views on medical and health research. The survey showed that an overwhelming majority of residents say it is important for the state to be a leader in education (89%) and in medical and health research (87%).



(L to R) Susan Dentzer; Michael Drake, M.D.; Joe Kanfer; Lucinda Maine, Ph.D., R.Ph.; Walter Koroshetz, M.D.; Sudip Parikh, Ph.D.; Thomas Zenty

Research!America President and CEO Honored for Leadership and Advocacy

Research!America president and CEO Mary Woolley was the recipient of the 2016 AcademyHealth Chair Award, recognizing her leadership and contributions to moving health services research into policy and practice to benefit Americans' health and health care. She accepted the award during AcademyHealth's Annual Research Meeting in Boston on June 27, urging attendees to reach out to lawmakers and candidates to ensure support for health care delivery research. Among past AcademyHealth Chair Award winners is the late Senator Edward Kennedy.

Woolley received the National Academy of Medicine's prestigious Adam Yarmolinsky Medal for her contributions to the Academy's mission of addressing important health issues and related policy to effect positive cross-sector change. "Serving the public's interest is what the National Academy of Medicine is all about. Adam Yarmolinsky epitomized that. He was clear about the importance of sensitivity to the public—including the political—frame of serving the public's interest. Yarmolinsky served several U.S. presidents with that sensitivity clearly in mind," Woolley said in her acceptance speech during the Academy's annual meeting on October 17.




(L to R) Victor Dzau, M.D., National Academy of Medicine, Research!America Board Member; Mary Woolley, Research!America; Jane Henney, M.D., University of Cincinnati

AMY HART

In thinking about threats to your health, how important is it that elected officials at all levels **listen to advice from scientists?**

Source: A Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in January 2016..



Motivating Research Advocates

● Research!America Advocacy Workshops

Throughout the year, Research!America conducts advocacy workshops with researchers, faculty, patient advocates and students to help them become stronger advocates for research and build relationships with the public, policymakers and the media. Here are some highlights of workshops held in 2016:

Connecting with Patients

"It's about being committed to turning the momentum of the last year into a movement that everyone can be a part of," said president and CEO Mary Woolley, addressing patients and researchers at the Scleroderma Foundation Patient Education Conference on the importance of advocacy. Patient advocates, Woolley said, are integral to improving the research and legislative landscape. She discussed the current state of federal health research agency budgets, shared relevant public opinion survey data and provided insights on how to effectively communicate with different audiences.

"It's about being committed to turning the momentum of the last year into a movement that everyone can be a part of."

Mary Woolley, CEO Research!America

Reaching Scientists

During a workshop with American Society for Bone and Mineral Research (ASBMR) members, Woolley said advocates must step up their engagement with policymakers, and provided updates on legislative issues related to research and health. She made recommendations on how to connect with policymakers and shared survey data on public perception of science and scientists. Finding common ground with policymakers is important, Woolley said, since researchers and policymakers both work to serve the public's interest. ASBMR President Douglas P. Kiel, M.D., MPH, said "a personal commitment to advocacy is crucial to attach a face to the important, lifesaving research we do, so that our policymakers and the general public remember the significance of supporting scientists."

Inspiring Early-Career Researchers

Research!America staff met with post-doctoral students and Ph.D. candidates at Johns Hopkins University to discuss the importance of advocacy. The workshop touched on the current political landscape, and highlighted the 21st Century Cures Act as an example of how advocacy works to garner bipartisan support from policymakers.



(L to R) Asegun Henry of Georgia Institute of Technology; Mohammad Khan, Emory University School of Medicine; Brion Bob, U.S. Department of Energy; Suzanne Ffolkes, Research!America; Lisa Richardson, Centers for Disease Control and Prevention; and Randall Guensler, Georgia Institute of Technology

SIGMA XI

They offered suggestions for engaging effectively with congressional staff, emphasizing the importance of putting a face on research. JHU students said they were inspired to get involved in advocacy after the workshop, and subsequently participated in a day of advocacy to call, tweet and email congressional leaders, urging them to increase research funding.

Public Policy, Advocacy and Science

A public policy panel discussion at the Sigma Xi Annual Meeting focused on the impact of policy decisions on research initiatives. Moderated by Research!America VP of Communications Suzanne Ffolkes, the panel discussed the effects of federal policies and major initiatives like the Cancer Moonshot and SunShot solar energy initiative on research and careers. The panelists, representing government and academic leaders, said major initiatives will help advance specific goals but federal support for other research must be sustained. Speakers also encouraged attendees, consisting of Sigma Xi members, professional scientists, engineers, and students, to do more public outreach to boost scientific literacy.

Giving Thanks to Public Health Heroes

On November 21, the Monday before Thanksgiving, Research!America and leading public health organizations recognized community health workers, biomedical researchers, epidemiologists, nurses, and many more who dedicate their time and energy to combat disease and build a healthier environment for Americans. In the face of major crises such as the Zika outbreak, the opioid epidemic, limited mental health resources and unsafe drinking water, these public health professionals continue working diligently to keep us safe.

"It's easy to miss public health successes—you don't see the heart attacks that don't happen, the years added to the lives of those who quit smoking, or the flu deaths avoided because of vaccines," said Thomas Frieden, M.D., MPH, director of the Centers for Disease Control and Prevention (CDC) in a statement. "To all who have dedicated their careers to help us live our lives to the fullest, thank you!"

National Institutes of Health Director Francis Collins, M.D., Rep. Joyce Beatty (D-OH-03), and U.S. Surgeon

General Vivek Murthy, M.D., were among this year's notable participants on social media.

"Public health workers save lives every day," Rep. Beatty wrote on Twitter. "Thank you for your commitment to our health and safety."

Murthy thanked the more than 6,700 U.S. Public Health Service Commissioned Corps officers "who have dedicated themselves to protecting the health of our nation."

The bipartisan co-chairs of Congressional Public Health Caucus, Representatives Rob Wittman (R-VA), Gene Green (D-TX), Kay Granger (R-TX), Lucille Roybal-Allard (D-CA), and Jim McGovern (D-MA) introduced a resolution (H.Con.Res.172), which expresses the sense of Congress that public health professionals should be commended for their dedication and continued service on Public Health Thank You Day.

Our partners this year included patient groups, scientific societies, industry experts, public health leaders, and members of academia. Visit www.publichealththankyou-day.org for a full list of partners.


U.S. Investments in Medical and Health R&D Report

United States medical and health research and development (R&D) investments grew 13.3% from 2013 to 2015, led by industry and the federal government, but remain a very small fraction of total health spending, less than five cents of every health dollar, according to "U.S. Investments in Medical and Health Research and Development," a report from Research!America. Foundations, voluntary health associations and professional societies increased their level of spending over the three-year period but industry, including pharmaceutical, medical technology, biotechnology and health IT companies, invests more in R&D than other sectors (65%).

"One sector cannot do it alone," said William Hait, M.D., Ph.D., global head, Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Research!America board member, emphasizing the importance of both public and private investments in R&D to support innovative research. "Initiatives like the Cancer Moonshot enable us to bring the best minds together, and collaborate to disrupt the progression of disease."

Most federal medical and health research money goes through the National Institutes of Health to fund research at universities, independent research institutes, and businesses nationwide. Federal funding must be increased and sustained to ensure "research and innovation continue to keep pace with saving and improving lives, and advancing the level of scientific opportunity,"

said Research!America chair The Honorable John Edward Porter in the report. A majority of Americans (76%) agree that basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government. More than half (54%) do not believe there is enough collaboration between academic, government and industry scientists on research projects to discover and develop new medicines.



Research Across the Continuum

● Congressional Briefings on Capitol Hill

Research!America organized congressional briefings on Capitol Hill, bringing together patient groups, industry, academia and private research institutions to connect with policymakers and communicate their research and the importance of funding for medical and health research.

Cancer Research

Research!America, in partnership with AcademyHealth, American Cancer Society and Celgene Corporation, convened a panel of experts for the congressional briefing, "Research Across the Continuum: Cancer from Bench to Bedside." Each speaker provided a unique perspective on the current state of cancer research, while also showcasing the interdependence of each stage of the research continuum. Lisa Simpson, M.B., B.Ch., MPH, president and CEO of AcademyHealth, moderated the discussion and noted how federal agencies such as the Agency for Healthcare Research and Quality, the National Institutes of Health, and the Food and Drug Administration all play integral roles in conducting research and funding innovations.

Panelists were Joel Beetsch, Ph.D., vice president of global patient advocacy and corporate affairs, Celgene; Jan Eberth, Ph.D., assistant professor, University of South Carolina; Michael Holtz, state lead ambassador for Tennessee, American Cancer Society Cancer Action Network; and Larry Kessler, Sc.D., professor, University of Washington School of Public Health.

Asthma and Allergy Research

AcademyHealth, Allergy and Asthma Network, Asthma and Allergy Foundation of America and GlaxoSmithKline joined Research!America to host a briefing that focused on the full research continuum, from basic to clinical to population and health care delivery research, and ultimately to patients. The briefing, "From Discovery to Delivery: Research at Work Against Allergies and Asthma," moderated by Dr. Lisa Simpson, illustrated the value of public and private sector research in the fight against asthma and allergies.

Panelists were Catherine Bonuccelli, M.D., therapeutic area head, respiratory, GlaxoSmithKline; Tyra Bryant-Stephens, M.D., founder and medical director, Community Asthma Prevention Program, The Children's Hospital of Philadelphia; Michael Cabana, M.D., MPH, professor of pediatrics, epidemiology & biostatistics, chief, division of general pediatrics, University of California, San Francisco; Kirk Druey, M.D., chief, molecular signal transduction section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases; and Vernetta Santos and family, patient advocates.



(L to R) Ellie Dehoney, Research!America; Michael C. Alfano, DMD, Ph.D.; Judith Jones, DDS, MPH, DScD; Beth Truett, B.S., MDiv; Fotinos Panagakos, DMD, Ph.D.; Marko Vujcic, Ph.D.

Oral Health Research

"Prevention is key when discussing oral health, if you can prevent oral diseases, you can prevent other serious health problems" like diabetes, stroke and heart disease, said Fotinos S. Panagakos, DMD, Ph.D., global director, scientific affairs, Colgate-Palmolive Co., during the congressional briefing, "Oral Health in an Aging Nation: An Unmet Public Health Challenge," hosted by Research!America and Colgate-Palmolive. Speakers discussed how unmet dental needs affect people's quality of life, nutrition and overall well-being, as well as the need to include dental health benefits in Medicare.

Panelists were Michael C. Alfano, DMD, Ph.D., president, Santa Fe Group Professor, dean and executive vice president emeritus, New York University; Judith Jones, DDS, MPH, DScD, director, Center for Clinical Research professor, Department of Health Policy & Health Services Research and Department of General Dentistry, Boston University Henry M. Goldman School of Dental Medicine; Beth Truett, B.S., MDiv, president and CEO, Oral Health America; and Marko Vujcic, Ph.D., chief economist & vice president, Health Policy Institute, American Dental Association.

Media Highlights of 2016

Thought-provoking commentary, up-to-the-minute interviews and articles about the election, medical innovation, science, 21st Century Cures, public health and the National Health Research Forum captured the interest of international, national and local media outlets in 2016. Highlights include:

Research!America president and CEO Mary Woolley's op-ed "When Will Candidates Close the Empathy Gap on Research for Health?" was published in **The Huffington Post**.

Following the passage of the 21st Century Cures Act, Woolley was quoted in the **Los Angeles Times** in support of the bill.

In a **New York Times** article about the Cancer Moonshot and Vice President Joe Biden's leadership, Woolley expressed her support for the initiative.

Regional **radio interviews** with Woolley focused on the Campaign for Cures national voter education initiative and the impact of federally-funded research in different states.


Research!America Chair the Honorable John Edward Porter said Newt Gingrich could help elevate the importance of medical research in the Trump Administration in **STAT News**.

Woolley discussed the importance of investments in global health to combat the Ebola virus in a **CNN** article.

Executive Director of the Concord Coalition Robert L. Bixby and Woolley co-wrote an op-ed in **The Philadelphia Inquirer** about the need to address structural problems in the federal budget.

Research!America VP of Communications Suzanne Ffolkes was quoted on **NPR's Marketplace** about advocating for medical and health research during the election cycle.

In a letter to the editor published in **The Boston Globe** in response to an article about the promise of genomic medicine, Woolley said that strengthening investments in research is key to accelerating medical progress.



In an **ABC News** article about gun violence, Woolley provided examples of how public health research has saved thousands of lives.

Ellie Dehoney, Research!America VP of Policy and Advocacy, was quoted on **NPR's—All Things Considered** about the 21st Century Cures Act.

Research!America news and advocacy messages were shared broadly via social media and other digital platforms, including Facebook, Twitter and Medium.

2016

Major Donors, Partners and Contributors

Visionaries

\$100,000+

Janssen Pharmaceutical
Companies of
Johnson & Johnson

Champions

\$50,000–\$99,999

American Medical
Association
Amgen
Burroughs Wellcome
Fund
Elsevier
Eli Lilly and Company
PCORI
Pfizer Inc
Rogers Family
Foundation
Rosenfeld Heart
Foundation
Susan Whitehead

Partners

\$25,000–\$49,999

AdvaMed (Advanced
Medical Technology
Association)
Aetna, Inc.
Alzheimer's Association
Astellas Pharma US, Inc.
BD
Colgate-Palmolive Co.
Georgia Research
Alliance
Gordon and Llura Gund
Howard Hughes Medical
Institute
Louisiana State
University
Merck & Co., Inc.
Partners HealthCare
System
PhRMA
Dr. Raymond and
Beverly Sackler
Sanofi
UCB, Inc.
UsAgainstAlzheimer's

Innovators

\$10,000–\$24,999

Battelle
Biogen
Biotechnology
Innovation
Organization
Bristol-Myers Squibb
David and Denise
Bunning
Celgene Corporation
The Cleveland Clinic
The Dana Foundation
Faegre Baker Daniels
Consulting
FasterCures, The Center
for Accelerating
Medical Solutions
Geoffrey Beene
Foundation
GlaxoSmithKline
Huntington National
Bank
Inter-University Council
of Ohio
Massachusetts Institute
of Technology (MIT)
Mayo Clinic
Northeast Ohio Medical
University
Novartis
The Rockefeller
University
Shire
Society for
Neuroscience
Louis W. Sullivan, M.D.
Takeda Pharmaceuticals
U.S.A., Inc.
University Hospitals
Weill Cornell Medicine
Whitehead Institute for
Biomedical Research
Mary Woolley

Advocates

\$1,500–\$9,999

AcademyHealth
American Heart
Association
Tenley E. Albright, M.D.
The ALS Association
Alzheimer's Drug
Discovery Foundation
Hortensia Amaro, Ph.D.
American Association for
the Advancement of
Science
American Association of
Cancer Research
American Association of
Colleges of Pharmacy
American Cancer
Society
The American College
of Neuropsychopharmacology
The American Society of
Microbiology
Ian Archer-Watters
The Baltimore Family
Fund
BMJ Publishing Group
Cold Spring Harbor
Laboratory
Edelman
Entertainment Industry
Foundation
EveryLife Foundation for
Rare Diseases
Joseph M. Feczko, M.D.
Jay A. Gershen, DDS,
Ph.D.
Mary J. C. Hendrix,
Ph.D., and Chuck
Craft
Hogan Lovells US LLP
Rush D. Holt, Ph.D.
The Johns Hopkins
University
Robert S. Langer, Sc.D.
Alan I. Leshner, Ph.D.
James L. Madara, M.D.
Lucinda L. Maine, Ph.D.,
RPh

March of Dimes
Foundation
Hon. Kweisi Mfume
National Disease
Research Interchange
(NDRI)
New York-Presbyterian
Hospital
Hon. John Edward
Porter
Laing Sisto Rogers
Larry J. Shapiro, M.D.
Spectrum Science
Communications
Reed V. Tuckson, M.D.,
FACP
University of Maryland,
School of Medicine
The University of Texas
MD Anderson Cancer
Center
Van Andel Research
Institute
Washington University
School of Medicine in
St. Louis
Wright State University
Elias and Nadia Zerhouni
Zogby Analytics

Supporters

\$500–\$1,499

Allergy & Asthma
Network
American Academy of
Arts & Science
American Association of
Colleges of Nursing
American Association of
Pharmaceutical
Scientists
Paul Berg, Ph.D.
William R. Brinkley, Ph.D.
Nancy Brown
Hon. Michael N. Castle
Mike Coburn
Council of Scientific
Society Presidents
Eleanor Dehoney
Susan Dentzer

Jack E. Dixon, Ph.D.
Victor Dzau, M.D.
Foundation for National
Institutes of Health
Karen Goraleski
William N. Hait, M.D.,
Ph.D.
Barbara C. Hansen, Ph.D.
John G. Hildebrand,
Ph.D.
Martha N. Hill, Ph.D., RN,
FAAN
JDRF
Elizabeth Baker Keffer
Robert Klein II, JD
Lewis-Burke Associates
LLC
Lundbeck, Inc.
Leah J. Mullin
National Association for
Biomedical Research
Oklahoma Medical
Research Foundation
Gilbert S. Omenn, M.D.,
Ph.D.
Oxford Bioscience
Partners
Herbert Pardes, M.D.
E. Albert Reece, M.D.,
Ph.D., MBA
Rebecca Rogers
Carol R. Scheman
Alan Schulman
M. Roy Schwarz, M.D.
Scleroderma Foundation
John R. Seffrin, Ph.D.
Gregory Sorensen, M.D.
Susan G. Komen
Craig B. Thompson, M.D.
WebMD Health Corp
M. Cass Wheeler

Research!America Staff

Mary Woolley
President and CEO

Barbara Love
Executive Assistant
to the President

Administrative

Mike Coburn
Executive Vice President &
Chief Operating Officer

Aimée Lefever
Director of Operations

Michelle Reddersen
Controller

Communications

Suzanne Ffolkes
Vice President,
Communications

Jennifer Santisi
Senior Manager of
Communications

Anna Briseño
Senior Manager of
Communications

Izzy Okparanta
Senior Communications
Specialist

Development and Membership

Donna McKelvey
Vice President,
Development and
Membership

Thayer Surette
Director of Development

Ted Brasfield
Senior Manager,
Membership Development

Policy and Advocacy

Ellie Dehoney
Vice President, Policy
and Advocacy

Sara Chang
Director of Policy and
Advocacy

Rachel Weissman
Manager of Policy
and Advocacy

Jacqueline Lagoy
Administrative Coordinator,
Policy and Advocacy

Burroughs Wellcome Fund Interns

Tristan Gray-Le Coz
Anna Hatch, Ph.D.
Valencia Hines
Meena Nayagam
Maria Perica
Dylan Simon
Brian Smith
Yue Yin

Science Policy Fellows

Caitlin Cotter, DVM, MPH
Jeffrey Wojton, Ph.D.

Research!America Leadership

● Officers



***The Honorable John Edward Porter**
Chair
Senior Advisor, Hogan
Lovells US LLP
United States Representative
(1980–2001)



***The Honorable Michael N. Castle**
Vice Chair
Partner
DLA Piper, LLP
Governor of Delaware
(1985–1992)
United States Representative
(1993–2011)



***Mary Woolley**
President
Chief Executive Officer
Research!America



***E. Albert Reece, M.D., Ph.D., MBA**
Secretary
Vice President of
Medical Affairs;
The John Z. And Akiko
Bowers Distinguished
Professor and Dean,
University of Maryland
School of Medicine



***Lucinda Maine, Ph.D., R.Ph.**
Treasurer
Executive Vice President &
Chief Executive Officer
American Association of
Colleges of Pharmacy

Board Members

Tenley E. Albright, M.D.
Director, Collaborative Initiatives
Massachusetts Institute of
Technology

Hortensia Amaro, Ph.D.
Associate Vice Provost for
Community Research Initiatives,
Dean's Professor of Social Work and
Preventive Medicine, University of
Southern California

***Georges C. Benjamin, M.D.**
Executive Director
American Public Health Association

***Nancy Brown**
Chief Executive Officer
American Heart Association

Susan Dentzer
President and
Chief Executive Officer
Network for Excellence
in Health Innovation

***Victor J. Dzau, M.D.**
President
National Academy of Medicine

Joseph M. Feczko, M.D.

***Jay A. Gershen, DDS, Ph.D.**
President
Northeast Ohio Medical University

***William N. Hait, M.D., Ph.D.**
Global Head
Janssen Research & Development,
LLC

Larry Hausner, MBA
President
ConStrat

Mary J.C. Hendrix, Ph.D.
President
Shepherd University

Martha N. Hill, Ph.D., R.N., FAAN
Dean Emerita; Professor of Nursing,
Medicine and Public Health
The Johns Hopkins University
School of Nursing

Rush D. Holt, Ph.D.
Chief Executive Officer
American Association for the
Advancement of Science

Harry Johns
President and
Chief Executive Officer
Alzheimer's Association

Elizabeth Baker Keffer
Managing Director and
Chief Network Officer
BDT Capital Partners

Debra R. Lappin, J.D.
Principal
FaegreBD Consulting

***Alan I. Leshner, Ph.D.**
Chief Executive Officer Emeritus
American Association for the
Advancement of Science

James L. Madara, M.D.
Chief Executive Officer and
Executive Vice President
American Medical Association

Mark McClellan, M.D., Ph.D., MPA
Director
Duke-Robert J. Margolis, M.D.,
Center for Health Policy
Duke University

***The Honorable Kweisi Mfume**
United States Representative
(1987–1996)

***Herbert Pardes, M.D.**
Executive Vice Chairman,
Board of Trustees
NewYork-Presbyterian Hospital

***Sudip S. Parikh, Ph.D.**
Senior Vice President &
Managing Director
DIA Americas

Harold L. Paz, M.D., MS
Executive Vice President
and Chief Medical Officer
Aetna, Inc.

Gary M. Reedy
Chief Executive Officer
American Cancer Society

***Amy Comstock Rick, J.D.**
President and
Chief Executive Officer
Food and Drug Law Institute

***Larry J. Shapiro, M.D.**
Spencer T. and Ann W. Olin
Distinguished Professor;
Executive Vice Chancellor for
Medical Affairs and
Dean Emeritus, School of Medicine
Washington University in St. Louis

Laing Rogers Sisto
Community Leader

Gregory Sorensen, M.D.
Executive Chairman
IMRIS

***Keith R. Yamamoto, Ph.D.**
Vice Chancellor for Science Policy
and Strategy;
Director, UCSF Precision Medicine;
Vice Dean for Research,
School of Medicine
University of California,
San Francisco

Elias A. Zerhouni, M.D.
President, Global Research &
Development
Sanofi
Former Director, National Institutes
of Health (2002–2008)

*Executive Committee Member

Emeritus Members

Dennis A. Ausiello, M.D.
Kenneth I. Berns, M.D., Ph.D.
William R. Brinkley, Ph.D.
Roger J. Bulger, M.D.
G. Steven Burrill
Gail H. Cassell, Ph.D.
Wendy Chaite, Esq.
Jordan J. Cohen, M.D.
Sam Donaldson
Robert Dresing
Myron Genel, M.D.
Irma E. Goertzen
M.R.C. Greenwood, Ph.D.
Elmer E. Huerta, M.D., MPH
Robert A. Ingram
Jackie Lovelace Johnson
Evan Jones
Hon. Patrick J. Kennedy
Caroline A. Kovac, Ph.D.
Philip R. Lee, M.D.
Ellen Levine
John P. Margaritis
Jewell Jackson McCabe
Catherine E. McDermott
Donnica L. Moore, M.D.

In Memoriam

Eugene Garfield, Ph.D., served as a member of Research!America's board from 2001 to 2010, and until his death as an Emeritus Director. Founding support for Research!America's *Garfield Economic Impact Award* was provided by the Eugene Garfield Foundation. The Award, established in 2002, recognized outstanding research demonstrating the economic impact of medical and health research. Garfield is widely known as the "father" of the impact factor, a key metric in journal publishing used by scientists across many research disciplines.

The Honorable Robert Michel was the U.S. Representative for Illinois's 18th congressional district from 1957 to 1995, and minority leader for 14 years, the longest-serving minority leader in the U.S. House. After leaving Congress, he served as senior advisor to the Campaign for Medical Research and worked for the lobbyist firm Hogan & Hartson (now Hogan Lovells) with the Honorable Paul G. Rogers, working successfully to increase funding for the National Institutes of Health. Michel was honored for his work with the *Edwin C.*

James E. Mulvihill, DMD
Elizabeth G. Nabel, M.D.
William D. Novelli
William A. Peck, M.D.
Edward E. Penhoet, Ph.D.
William L. Roper, M.D., MPH
Leon E. Rosenberg, M.D.
Isadore Rosenfeld, M.D.
Raymond R. Sackler, M.D.
Charles A. Sanders, M.D.
Mitchel Sayare, Ph.D.
Carol R. Scheman
M. Roy Schwarz, M.D.
Susan C. Scrimshaw, Ph.D.
John R. Seffrin, Ph.D.
Randolph Siegel
Samuel C. Silverstein, M.D.
Hon. Louis W. Sullivan, M.D.
Hon. Billy Tauzin
Reed V. Tuckson, M.D.
Christopher A. Viehbach
M. Cass Wheeler
John Whitehead
Ruth Wooden
Judy Woodruff
James B. Wyngaarden, M.D.

Whitehead Award for Medical Research Advocacy at the 2004 Advocacy Awards Dinner.

Former First Lady Nancy Reagan was honored with the 2006 Research!America Legacy Award for her long-standing commitment and distinguished leadership on behalf of medical and health research, particularly Alzheimer's and embryonic stem cell research.

Actress Mary Tyler Moore served as the International Chairman of the Juvenile Diabetes Research Foundation (JDRF). Research!America honored Moore at the 2005 Advocacy Awards Dinner, where she accepted an award on behalf of the JDRF, which was saluted as an "organization that has distinguished itself by its advocacy."

Harrison Spencer, M.D., MPH, President and CEO of the Association of Schools of Public Health, served as a member of Research!America's board from 2006 to 2010. Spencer was widely recognized for his clinical public health work, and research into infectious disease prevention and control.